Replies to post #239747 on Biotech Values

[DewDiligence]

BMY will bank $1.3B from selling its 11.5% XLRN stake in MRK’s buyout, assuming the deal goes through:

https://finance.yahoo.com/news/bristol-myers-plans-exit-acceleron-023231535.html

[DewDiligence]

MRK—Sotatercept phase-3 in PAH hits primary endpoint:

https://finance.yahoo.com/news/merck-announces-positive-top-line-104500840.html

Sotatercept is the drug MRK picked up in the $11.5B XLRN acquisitions last year (#msg-166156870).